Register or Sign in to Save this opportunity, or Send an Inquiry.
End of Phase III Products for the Treatment of Irritable Bowel Syndrome (IBS) Sought
Leiras Takeda Pharmaceuticals Finland flag Finland
Abstract ID:
The new product sought should act as complimentary product to our corporate pipeline product vedolizumab
Send an Inquiry
RE:
Participants
You

The new product sought should act as a complimentary product to our corporate pipeline product vedolizumab.

Type of Business Relationship Sought

No co-funding or co-development expected from Takeda in Nordics

FEATURED
Last Updated Aug 2014
Technology Type
Phase of Development CLINICAL TRIALS
CORPORATION

Opportunity Contact